Company: PSTV
Filing Date: 2025-08-12
Form Type: 8-K
Source: 0001193125-25-179012
Chunk: 0

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-08-12
Form: 8-K
Item: Item 5.07
Chunk 0
---
Item 5.07      Submission of Matters to a Vote of Security Holders.  

The 2025 Annual Meeting of Stockholders of Plus Therapeutics, Inc. (the “ Company”) was held on August 7, 2025 (the “ Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on five proposals, as described in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on July 21, 2025 (the “ Proxy Statement”).

The Company had 60,490,101 shares of common stock issued and outstanding at the close of business on June 18, 2025, the record date for eligibility to vote at the Annual Meeting. The holders of 29,973,272 shares of the Company’s issued and outstanding common stock were represented in person virtually or represented by valid proxy at the Annual Meeting, constituting a quorum.

The vote results detailed below represent final results as certified by the inspector of elections.

Proposal No. 1 - Election of Directors.

The Company’s stockholders elected the following persons, who were listed in the Proxy Statement, to the Board of Directors of the Company (the “ Board”) to hold office for a term expiring at the Company’s Annual Meeting of Stockholders in 2026 and until each such person’s successors is duly elected and qualified, or until his or her earlier death, resignation or removal:

 ───────────────────────────────────────────────────────────────────────────
  Howard Clowes                   18,904,550      774,122      10,294,600  
  An van Es-Johansson, M. D.      18,743,348      935,324      10,294,600  
  Richard J. Hawkins              18,920,875      757,797      10,294,600  
  Marc H. Hedrick, M. D.          18,764,355      914,317      10,294,600  
  Robert Lenk, Ph. D.             18,934,411      774,261      10,294,600  
  Kyle Guse, Esq., MBA, CPA       18,698,728      979,944      10,294,600  

Proposal No. 2 - Issuance Proposal.

The Company’s stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the potential issuance